Aprea Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Aprea Therapeutics, Inc.'s free cash flow has increased -4.99% from $-13.57M last year to $-12.89M, signaling increasing performance

Aprea Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Aprea Therapeutics, Inc. has insufficient data to evaluate this check.

Aprea Therapeutics, Inc. has a net cash position, so leverage is healthy.

Aprea Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Aprea Therapeutics, Inc.'s profit margin has decreased (1.07K%) in the last year from -862.43% to -10.12K%, signaling decreasing performance

Aprea Therapeutics, Inc.'s short-term assets of $15.56M exceed its short-term liabilities of $2.76M

Aprea Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Aprea Therapeutics, Inc.'s return on equity of -59.54%, is lower than 15.00%, indicating bad performance

Aprea Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Aprea Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Aprea Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Aprea Therapeutics, Inc. has negative free cash flow, indicating cash burn

Aprea Therapeutics, Inc.'s yearly earnings has increased -2.77% since last year from $-12.96M to $-12.60M, signaling increasing performance

Aprea Therapeutics, Inc.'s yearly revenue has decreased 100.00% since last year from $1.50M to $0.00, signaling decreasing performance

ROIC -29.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Aprea Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Aprea Therapeutics, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Aprea Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Aprea Therapeutics, Inc. has insufficient data to evaluate this check.

Aprea Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aprea Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Aprea Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Aprea Therapeutics, Inc. has insufficient data to evaluate this check.

Aprea Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Aprea Therapeutics, Inc. has a price-to-book ratio of 0.12x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Aprea Therapeutics, Inc. has a price-to-sales ratio of 41.84x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue